Efficacy of clofazimine and nitazoxanide combination in treating intestinal cryptosporidiosis and enhancing intestinal cellular regeneration in immunocompromised mice

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Esmat M.; Abdel-Aal A.A.; Shalaby M.A.; Badawi M.; Elaskary H.; Yousif A.B.; Fahmy M.-E.A.

Journal: Food and Waterborne Parasitology

Publisher: Elsevier Inc.

Publication Date: June 2022

Volume / Issue: Volume 27

Article No.: e00161

ISSN: 24056766

DOI: 10.1016/j.fawpar.2022.e00161

Scopus: View on Scopus

Document Type: Article

Access: All Open Access; Gold Open Access; Green Open Access


Authors and Affiliations

Esmat M., Department of Medical Parasitology, Faculty of Medicine, Misr University for Science and Technology, 6th October city, Egypt; Abdel-Aal A.A., Department of Medical Parasitology, Faculty of Medicine, Cairo University, Egypt, Department of Postgraduate Studies & Scientific Research, Armed Forces College of Medicine (AFCM), Cairo, Egypt; Shalaby M.A., Medical Parasitology Department, Theodor Bilharz Research Institute (TBRI), Giza, Egypt; Badawi M., Department of Pathology, National Research center, Giza, Egypt; Elaskary H., Depatment of Medical Parasitology, Faculty of Medicine, Beni-Suef University, Beni Suef, Egypt; Yousif A.B., Department of Medical Parasitology, Faculty of Medicine, Fayoum University, Faiyum, Egypt; Fahmy M.-E.A., Medical Parasitology Department, Theodor Bilharz Research Institute (TBRI), Giza, Egypt


Abstract

Cryptosporidium is a widely distributed food and water-borne enteric protozoan that affects a wide range of vertebrates, resulting in life-threatening consequences, particularly in immunocompromised hosts. The lack of effective anti-cryptosporidial drugs may be related to the parasite's unique intestinal location, plus the lack of studies on the process by which the protozoan is able to impair intestinal cellular function. The present work aimed to assess the effect of clofazimine (CFZ), an FDA-approved drug for the treatment of leprosy, as an anti-cryptosporidial drug, using transmission electron microscopy (TEM) and an immunocompromised mouse model. The affected intestinal mucosa with parasitic stages in the infected non-treated group showed signs of severe cellular degeneration, including the loss of tight junctions, deformed and damaged microvilli and irregularly distributed nuclei with a severely vacuolated cytoplasm. Comparatively, nitazoxanide (NTZ) monotherapy showed the lowest efficacy as the drug was associated with the lowest rate of oocyst shedding. In addition, NTZ treatment failed to achieve the return of complete cellular function; abnormalities were evident in the microvilli, cytoplasmic organelles and nuclear features. Clofazimine demonstrated an improvement of the mucosal cellular components, including mitochondria and significantly reduced oocyst shedding. Combined treatment with low-dose CFZ and half-dose NTZ resulted in a significant improvement in the enterocyte cellular structures with an absence of intracellular parasitic stages. These results indicate that CFZ, a safe and readily prescribed drug, effectively reduces cryptosporidiosis when used in combination with only half the dose of NTZ. Used in combination, these drugs were shown to be efficient in regaining intestinal cellular activity following Cryptosporidium-induced functional damage in an immunocompromised mouse model. © 2022 The Authors


Keywords

Clofazimine; Cryptosporidium; Intestinal renewal; TEM; Ultrastructure; nitazoxanide; animal cell; animal experiment; animal model; Article; cell function; cell organelle; combination drug therapy; comparative study; controlled study; cryptosporidiosis; Cryptosporidium parvum; drug efficacy; female; immunosuppressive treatment; intestine cell; intestine mucosa; leprosy; microvillus; monotherapy; mouse; nonhuman; tight junction; transmission electron microscopy


Citation Information

Scopus Citations: 18


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Corrigendum to ‘Eco-friendly approach for the removal and simultaneous detection of cyanide toxins from drinking and wastewater sources’ [Environ. Pollut. 385 (2025) 127094]

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer